Understand the source comparison
Peptide Class Comparison for ADHD Symptom Management
Cerebrolysin BDNF upregulation, synaptic plasticity enhancement Inattentive-type: working memory deficits, sustained attention 2–3 times per week, 5–10 mL per dose Most evidence-backed for cognitive enhancement; requires IM injection Dihexa c-Met receptor acti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF upregulation, synaptic plasticity enhancement
- Inattentive-type: working memory deficits, sustained attention
- 2–3 times per week, 5–10 mL per dose
- Most evidence-backed for cognitive enhancement; requires IM injection
- Dihexa
- c-Met receptor activation, dendritic spine formation
- Task initiation, mental clarity, cognitive flexibility
- Daily, 1–5 mg subcutaneous
- Potent neuroplastic effects but limited human safety data
- P21
- CNTF-derived nootropic, neuroprotection
- Mental fog, processing speed, verbal fluency
- 3–4 times per week, 5–20 mg subcutaneous
- Well-tolerated, subtle effects; best as adjunct therapy
- Thymalin
- Immune modulation, CNS inflammation reduction
- Combined-type with inflammatory markers
- 2 times per week, 10–50 mg subcutaneous
- Addresses inflammation-driven cognitive impairment; indirect mechanism